Key Takeaways
- Resilient growth despite category corrections: Domestic volume grew 8% aided by Dermicool, while pain management and healthcare ranges corrected 30% and 25% respectively on a high COVID base.
- Gross margin contracted 340 bps to 62.6% on raw material inflation and an adverse portfolio mix; pressure persists in Q2 but is expected to ease in H2.
- International business surged 45% led by MENA and SAARC, though management flagged this pace is not sustainable and guided to decent double-digit growth ahead.
- Dermicool integration begins 1st August: the brand's true earnings benefit will only materialize when summer loading starts in JFM and the April-June quarter next year.
- What to watch next quarter: whether rural demand shows any uptick after no improvement through July, the pace of gross margin recovery as high-cost inventory clears, and early signals on Dermicool's distribution transition.
Category Headwinds & Offsetting Growth
- Pain management and healthcare corrected sharply: pain management down 30% and healthcare down 25% (led by immunity) against a base of 70% and 59% growth last year respectively. Management is explicit that matching last year's numbers is not in targets.
- Immunity demand collapsed to below pre-COVID levels: across all immunity categories, levels seem to have gone back to pre-COVID levels with possibly even more pressure; one hypothesis is consumers are still carrying stocks from purchases made in October-December last year.
- Core brands filled the gap: Navratna, Kesh King, Fair and Handsome, and international business together delivered 10% overall revenue growth excluding Dermicool, offsetting the pain and healthcare corrections.
- Navratna still in decline on a three-year basis: the last two seasons saw steep declines; growth returned this quarter and continued in July, but full recovery may take one or two years.
- Kesh King recovery is demand-led, not just distribution: growth driven by multiple initiatives, particularly in shampoo through sachets and other efforts, reflecting overall trust in the brand rather than purely expanded reach.
Mohan Goenka: "But it is not possible to match the numbers of last year. And we haven't taken that in our targets also, honestly."
Dermicool Acquisition & Integration
- Distribution transitions 1st August 2022: the existing distribution agreement with Reckitt ends and the brand moves entirely into Emami's fold; manufacturing remains with the existing third-party for now.
- Q2 contribution will be negligible: prickly heat season is over, so sales become almost nil in the September quarter; the true benefit will be realized when loading starts in JFM and the April-June quarter, which is when the brand's full potential will be captured.
- Extensions are in the pipeline but distant: new products or categories under the Dermicool brand are being worked on, though management cautioned it will take a while to launch some of them.
- Seasonality is accepted, not a problem to fix: management has no deliberate plan to address Dermicool's seasonal nature; brand acquisition decisions are opportunistic and seasonal fit is not a disqualifier if the asset fits the overall scheme.
Mohan Goenka: "So practically the sales become almost negligible. And prickly heat quickly there is no season, honestly."
Margins & Cost Pressures
- Gross margin fell 340 bps to 62.6%: driven primarily by high raw material inflation and an adverse portfolio mix (last year's base quarter had high-margin immunity and pain management selling in extraordinary volumes). Dermicool's lower margin had only a minor impact.
- Q2 will still see margin pressure: raw material stocks were bought at higher cost and will flow through the P&L in the September quarter; pressure will definitely ease in the second half.
- Full-year gross margin decline capped at 2%: management expects the annual impact not to exceed a 2 percentage point decline, implying recovery in H2 as input costs moderate and mix normalizes.
- A&P spend planned at 17-18% of sales for the year: investment intensity remains high despite the margin squeeze, with management optimistic that benefits will accrue once market conditions improve.
- Full-year blended price increase expected at 4-4.5%: pricing actions are being taken but are not sufficient to fully offset the input cost inflation absorbed in the first half.
Channel & Distribution Momentum
- Modern trade grew 42% and e-commerce grew 55%: their combined share of domestic sales rose to 15.8% (8.2% and 7.6% respectively), driven by store expansion, in-store visibility investments, and e-commerce-specific SKUs.
- Modern trade expansion is store-led and investment-backed: standalone store coverage reached ~6,000 outlets growing ~80%, while large hyper stores received significant investment under project 'Midas' for in-store visibility and promoter presence.
- E-commerce growth is structural, not promotional: large packs and platform-specific SKUs are growing faster; the team has been doubled and critical account management implemented to sustain momentum.
- Quick commerce presence is established but tiny: presence exists on all quick-commerce platforms, though SKU presence is very limited and sales numbers are small; management declined to quantify the contribution.
- Bridge packs gaining traction without margin dilution: INR20 Navratna, INR49 Kesh King (30 ml), and Fair and Handsome (30 g) bridge packs have seen phenomenal market acceptance, reaching 60-70% of core brand distribution; margins are not dilutive on the Kesh King pack.
Rural & Healthcare Distribution Build-Out
- Rural growth ex-balms was 21%: stripping out the pain portfolio, rural growth is faster than wholesale at the company level, aided by the Khoj project contributing ~1.2% incremental growth.
- No demand uptick visible yet: rural headwinds and economic slowdown persist; management saw no improvement at end-of-June or in July, and growth is being driven by distribution initiatives rather than demand recovery.
- Rural footprint expanding aggressively: 453 people added on ground, taking manpower from ~900 to ~1,300 and reaching 41,000 towns and villages; the bulk of expansion for this financial year will be in H2, targeting close to 50,000 by year-end.
- Healthcare OTC distribution being seeded for H2 payoff: plans to add ~20% outlets and increase rural footprint by 20%; results are expected in the second half given the initial seeding time required for new coverage to generate sales.
- Bangladesh investment deepening: decent growth was registered despite Ramadan and both Eids falling in Q1; distribution steps and systems automation are complete, with close to 130,000 outlets mapped; management direction and time allocation will increase given bigger perceived opportunities.
Vinod Rao: "So the net of portfolio without balms, without pain portfolio, our rural is actually growing at 21%. So, it's doing well for us."
International Business
- International delivered 45% growth: driven by MENA and SAARC regions, with all major brands performing well; fundamental growth came from almost every market on account of stepped-up brand-building activities and resolution of some distribution issues.
- The 45% pace is not repeatable: management guided that future quarters will see decent double-digit growth, not the elevated Q1 rate, partly because the base quarter last year was not as high a growth base.
- Country-specific issues are resolving: the Uzbekistan issue is likely to be sorted within the month; Sri Lanka currency issues should be behind in a couple of months; Nepal is facing extremely tight liquidity but remains part of the growth story.
Vivek Dhir: "So despite the macroeconomic issues in Russia and Ukraine, we have been able to register a growth in quarter one."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin recovery | Pressure eases as high-cost RM inventory clears; full-year decline capped at 2% | H2 FY23 |
| Dermicool earnings contribution | True benefit realized when summer loading starts | JFM and April-June quarter |
| International growth | Decent double-digit growth in every quarter (not 45%) | Every quarter ahead |
| Rural footprint expansion | Reach close to 50,000 towns and villages | By FY23 year-end |
| Healthcare OTC distribution | Add ~20% outlets and increase rural footprint by 20%; results expected in H2 | H2 FY23 |
| A&P spend | Maintained in the range of 17-18% of sales | Full year FY23 |
| Blended price increase | 4% to 4.5% for the full year | Full year FY23 |
| Navratna recovery | Return to prior peak levels if current growth trend sustains | One to two years |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | ₹778 cr, +18% YoY on a high base of 37% growth in Q4 FY22 |
| Domestic sales growth | +13% YoY on a high base of 42%, volume growth of 8% |
| International business growth | +45% YoY on a base of 17% |
| Overall volume growth | ~10% |
| Gross margin | 62.6%, contracted 340 bps YoY due to inflation and adverse portfolio mix |
| EBITDA | ₹173 cr, +2% YoY |
| Adjusted PAT | ₹138 cr, flat YoY |
| Blended price increase | 4–4.5% taken across portfolio; full-year expected in same range |
| A&P spend guidance | 17–18% of sales planned for FY23 |
| Gross margin guidance (FY23) | Decline not expected to exceed 2% for the full year |
| Effective tax rate guidance | ~18% for remaining quarters, including MAT credit |
| Dermicool amortization (going forward) | ~₹22 cr per quarter for Dermicool and other brands |
| Navratna range growth | +29% YoY |
| Kesh King range growth | +20% YoY |
| Male Grooming growth | +32% YoY |
| 7 Oils in One growth | +45% YoY |
| BoroPlus range growth | Flat YoY; +6% on a three-year CAGR basis |
| Pain management category | −30% YoY; +10% on a three-year CAGR basis |
| Healthcare range | −25% YoY, led by immunity portfolio; +13% on a three-year CAGR basis |
| Domestic portfolio ex-pain, healthcare, Dermicool | +30% value growth, +24% volume growth |
| Dermicool contribution to domestic sales | ~8% |
| Dermicool Q1 sales | ~₹63 cr (per an analyst's math) |
| Modern trade growth | +42% YoY; contribution at 8.2% of domestic sales |
| E-commerce growth | +55% YoY; contribution at 7.6% of domestic sales |
| CSD growth | +23% YoY |
| Rural coverage | 41,000 towns and villages, up from ~32,000; target ~50,000 by year-end |
| Project Khoj rural manpower | ~1,300 people on ground, up from ~900 |
| Rural growth ex-pain portfolio | +21% |
| Kesh King shampoo share | ~25% of Kesh King portfolio |
| Bridge packs contribution | 2–3% of sales; reached 60–70% of core brand distribution |